Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

• DOI: 10.1371/journal.pone.0063479
• Publication Date: 2013-05-21T21:12:00Z
• Authors: Ajay K. Kakkar; Iris Mueller; Jean-Pierre Bassand; David A. Fitzmaurice; Samuel Z. Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y. H. Lip; Lorenzo G. Mantovani; Alexander G. G. T...; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W. A. Verheugt
• Keywords: Stroke

Background Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk stroke, from a worldwide perspective. The aim this study was to describe baseline characteristics initial therapeutic management non-valvular across spectrum sites which these treated. Methods Findings Global Anticoagulant Registry in FIELD (GARFIELD) is an observational newly diagnosed fibrillation. Enrollment into Cohort 1 (of 5) took place between December 2009 October 2011 540 19 countries Europe, Asia-Pacific, Central/South America, Canada. Investigator representative distribution care settings each country. comprised 10,614 adults (≥18 years) within previous 6 weeks, ≥1 investigator-defined stroke factor (not limited those existing risk-stratification schemes), regardless therapy. Data collected included demographics, medical history, setting, nature fibrillation, treatments initiated diagnosis. mean (SD) age population 70.2 (11.2) years; 43.2% were women. Mean±SD CHADS2 score 1.9±1.2, 57.2% had ≥2. Mean CHA2DS2-VASc 3.2±1.6, 8,957 (84.4%) Overall, 38.0% ≥2 did not receive anticoagulant therapy, whereas 42.5% low (score 0) received Conclusions These contemporary end vitamin K antagonist-only era, indicate that drugs frequently being used according scores guidelines, overuse underuse high stroke. Trial Registration ClinicalTrials.gov TRI08888